News Headline Summary
Bristol Myers (BMY) says US patent on Hepatitis B drug Baraclude invalidated by Delaware federal court
- Co. loses patent challenge from generic drug maker Teva.
Reaction details (14:38)
- In immediate reaction, Co. shares are unmoved, trades at USD 36.83.
12 Feb 2013 - 14:33
Subscribe Now to RANsquawk
Click here for a 1 week free trial
RANsquawk provides audio news and commentary for over 15,000
professional traders and brokers worldwide. Services include:
Real-time audio coverage from 0630 to 2200 London time plus Asia-Pac 2200 to 1000 London time
Teams of analysts covering equities, fixed income, FX, energy, and metals markets
Real-time scrolling news service with instant analysis
Daily and weekly pre-market research and calendars
Video updates covering near-term key risk events & primary trading themes
One-to-one chat with our expert analysts